ClinicalTrials.gg
CompletedNCT05280483Updated Aug 12, 2024

ABSK021 Food Effect Study in Healthy Subjects

A Phase 1 interventional study of ABSK021 with fed state and ABSK021 with fasted state in Neoplasms, sponsored by Abbisko Therapeutics Co, Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-12.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a randomized, open-label, two-sequence, two-cycle, cross-over study to evaluate the relative bioavailability of ABSK021 after single-dose fasting and high-fat postprandial administration in healthy subjects

Read the detailed description

This is a single-center, arandomized, open label, two-sequence, two-cycle, cross-over study. Up to 16 healthy subjects will be enrolled in this study. Subjects will be randomized into sequence A or sequence B (8 subjects in each study sequence), and receive single oral doses of ABSK021 on 2 occasions separated by a washout period of at least 14 days (7 half-life of ABSK021 in human). Screening will occur up to 28 days prior to the first dose. And the end of treatment visit will occur 14 days after the last dose of ABSK021.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 16 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects (male or female), age greater than or equal to 18 years and less than or equal to 45 years, single-sex subjects should no less than 4;
  2. Weight ≥50 kg (≥45 kg for female), and have a (BMI) between 19 and 28 (including 19 and 28) at screening, BMI = weight (kg) / height (m) 2;
  3. Physical examination, clinical laboratory examination and other related examinations are normal or acceptable deviations that are judged to be not by the investigator;
  4. Male or female subjects with must agree to use effective during the study and within 6 months after the administration of the last dose (see 5.4 for details), and sperm donation is not allowed for male subjects during the study; female subjects must be non-pregnant and non-lactating;pregnancy is defined as post-conception until termination of pregnancy in female, which determined by laboratory human chorionic gonadotropin (hCG) testing within 7 days prior to the first dose of this study;
  5. Volunteer to participate in this study, understand the study procedures and sign the prior to any study specific procedures, good compliance and willing to follow study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Have a history of or current cardiovascular, respiratory, hematological, hepatic, renal, gastrointestinal, endocrine, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study;
  2. Have known or ongoing psychiatric disorders that would interfere with study participation as determined by the investigator;
  3. Have known allergy to any drug or food;
  4. Have participated in a clinical trial involving an product within the last 3 months;
  5. Have previously completed or withdrawn from this study or any other study investigating ABSK021, and have previously received the investigational product;
  6. Have used drugs or substances that are known to be strong inhibitors or inducers of within 14 days prior to the first dose (include grapefruit juice, grapefruit hybrids, pomegranates, starfruits, pomelos, Seville oranges or juice or products);
  7. Have known factors that significantly affect drug absorption, distribution, metabolism, excretion, such as inability to take oral medication or significant nausea and vomiting, and malabsorption;
  8. Unwilling to comply with the dietary requirements/restrictions during the study, the dietary requirements: (i) consume only the meals provided by the research center during inpatient visits, (ii) refrain from consuming strong inhibitors or inducers of CYP3A4 during the study.
  9. Have an average weekly alcohol intake that exceeds 14 units within 3 months prior to screening (1 unit of alcohol is approximately 360mL of beer or 45mL of spirits with 40% alcohol content or 150mL of wine), positive for alcohol screening, or unwilling to abide by alcohol restrictions as specified in Section 5.3.3;
  10. Smoking more than 5 cigarettes per day (or equivalent in tobacco or nicotine products) within 3 months prior to screening, or unwilling to abide by smoking restrictions as specified in Section 5.3.3;
  11. Have a history of, in the opinion of the investigator, excessive methylxanthine/caffeine use within the previous 6 months, or unwilling to abide by restrictions as specified in Section 5.3.3. Excessive intake is defined as more than 6 units of caffeine per day; one caffeine unit is contained in 177 mL of coffee, 355 mL of tea, 355 mL of cola, or 85g of chocolate;
  12. Any positive result on screening for serum surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis B e antibody (HBeAb), hepatitis B core antibody (HBcAb), virus (HCV) antibody and (HIV) antibody;
  13. have a recent history (\<45 days prior to the first dose) of a bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection, or significantly abnormal CT examination results of chest as determined by the investigator;
  14. Known history of drug abuse or have the positive results of drug abuse screening;
  15. Have used or intend to use over-the-counter or prescription medication , including herbal medications, within 14 days prior to dosing and during the study;
  16. Plasma donation within 30 days prior to screening or any blood donation/blood loss >500 mL during the 3 months prior to screening;
  17. Have received (s) within 2 months prior to screening, or intend to during the study;
  18. The personnel involved in the planning and/or conduct of the study and their immediate family members (applies to Abbisko staff, CRO staff, and staff at the study site);
  19. Abnormal vital signs, including:

    1. Ear temperature >37.5℃;
    2. Pulse>100 beats/min, or \<50 beats/min;
    3. Systolic blood pressure ≥140 mmHg or \<90 mmHg, diastolic blood pressure ≥90 mmHg or \<50 mmHg;
  20. History of gastric and intestinal surgery, or other surgical history that affects drug absorption (except appendicitis surgery);
  21. Prolonged corrected for heart rate using Fridericia's formula (QTcF) >450 ms (female >480 ms), or family history of long QT syndrome, or have an abnormal with clinical symptoms as determined by the investigator;
  22. Any other clinically significant comorbidities, which in the judgment of the Investigator, could compromise compliance with the protocol, interfere with the interpretation of study results, or predispose the patient to safety risks.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Fed states in healthy subjects

    A single 25mg dose of ABSK021 administered in a fed state.

    Drug: ABSK021 with fed state

  • Experimental
    Fasted states in healthy subjects

    A single 25mg dose of ABSK021 administered in a fasted state.

    Drug: ABSK021 with fasted state

Interventions

  • DrugABSK021 with fed state

    25 mg ABSK021 (1x25 mg ABSK021 capsule) with food

  • DrugABSK021 with fasted state

    25 mg ABSK021 (1x25 mg ABSK021 capsule) without food

06

What researchers measure

Primary outcomes

  1. Cmax

    Pharmacokinetics parameters in fasting state and fed state

    Time frame: 4 weeks

  2. AUC0-∞

    Pharmacokinetics parameters in fasting state and fed state

    Time frame: 4 weeks

  3. AUC0-t

    Pharmacokinetics parameters in fasting state and fed state

    Time frame: 4 weeks

  4. Tmax

    Pharmacokinetics parameters in fasting state and fed state

    Time frame: 4 weeks

Secondary outcomes

  1. Adverse Events

    Safety and tolerability measure by number of subjects who experience adverse events

    Time frame: Through study completion, an average of 4 weeks

07

Study locations

1 site
  • Huashan Hospital Fudan University
    Shanghai, Shanghai 201203, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Aug 2022, 1 month.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 1 month is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
Mar 15, 2022
StartActual
Jul 23, 2022
Primary completionActual
Aug 31, 2022
CompletionActual
May 26, 2023
Last update
Aug 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05280483
Responsible party
Sponsor
First posted
Mar 15, 2022
Start date
Jul 23, 2022
Primary completion
Aug 31, 2022
Completion
May 26, 2023
Last update
Aug 12, 2024

Study contacts

Jing Zhang
principal investigator · Shanghai, China

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion